These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 16247589)

  • 1. Rasburicase treatment in severe tophaceous gout: a novel therapeutic option.
    Moolenburgh JD; Reinders MK; Jansen TL
    Clin Rheumatol; 2006 Sep; 25(5):749-52. PubMed ID: 16247589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urate oxidase (rasburicase) for treatment of severe tophaceous gout.
    Vogt B
    Nephrol Dial Transplant; 2005 Feb; 20(2):431-3. PubMed ID: 15673692
    [No Abstract]   [Full Text] [Related]  

  • 3. Dual energy computed tomography for quantification of tissue urate deposits in tophaceous gout: help from modern physics in the management of an ancient disease.
    Bacani AK; McCollough CH; Glazebrook KN; Bond JR; Michet CJ; Milks J; Manek NJ
    Rheumatol Int; 2012 Jan; 32(1):235-9. PubMed ID: 20016988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resolution of massive tophaceous gout with three urate-lowering drugs.
    Mejía-Chew C; Torres RJ; de Miguel E; Puig JG
    Am J Med; 2013 Nov; 126(11):e9-10. PubMed ID: 23978312
    [No Abstract]   [Full Text] [Related]  

  • 5. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study.
    Richette P; Brière C; Hoenen-Clavert V; Loeuille D; Bardin T
    J Rheumatol; 2007 Oct; 34(10):2093-8. PubMed ID: 17896799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urate oxidase (rasburicase) for treatment of severe acute gout: a case report.
    Wipfler-Freibmuth E; Dejaco C; Duftner C; Gaugg M; Kriessmayr-Lungkofler M; Schirmer M
    Clin Exp Rheumatol; 2009; 27(4):658-60. PubMed ID: 19772802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy.
    Dalbeth N; Doyle AJ; McQueen FM; Sundy J; Baraf HS
    Arthritis Care Res (Hoboken); 2014 Jan; 66(1):82-5. PubMed ID: 23836458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rasburicase for tophaceus gout treatment].
    Ribeiro A; Bogas M; Costa J; Costa L; Araújo D
    Acta Reumatol Port; 2009; 34(3):551-4. PubMed ID: 19820680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystal arthritis. Intensive urate-lowering therapy improves structural joint damage in patients with tophaceous gout.
    Buckland J
    Nat Rev Rheumatol; 2013 Sep; 9(9):506. PubMed ID: 23897441
    [No Abstract]   [Full Text] [Related]  

  • 10. Reversal of chronic refractory tophaceous gout with erosions with pegloticase.
    Yeter KC; Ortiz EC; Arkfeld DG
    Int J Rheum Dis; 2013 Jun; 16(3):369-70. PubMed ID: 23981765
    [No Abstract]   [Full Text] [Related]  

  • 11. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
    Biggers K; Scheinfeld N
    Curr Opin Investig Drugs; 2008 Apr; 9(4):422-9. PubMed ID: 18393109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegloticase for treating refractory chronic gout.
    George RL; Sundy JS
    Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegloticase and the patient with treatment-failure gout.
    Dave AJ; Kelly VM; Krishnan E
    Expert Rev Clin Pharmacol; 2012 Sep; 5(5):501-8. PubMed ID: 23121270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout.
    Berhanu AA; Krasnokutsky S; Keenan RT; Pillinger MH
    Semin Arthritis Rheum; 2017 Jun; 46(6):754-758. PubMed ID: 27769591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A challenging case of gout and failure of anti-TNF therapy- are current treatments adequate?
    Nisar MK; Baburaj K
    Int J Rheum Dis; 2011 Aug; 14(3):e42-3. PubMed ID: 21816013
    [No Abstract]   [Full Text] [Related]  

  • 16. Learning how and when to employ uricase as bridge therapy in refractory gout.
    Terkeltaub R
    J Rheumatol; 2007 Oct; 34(10):1955-8. PubMed ID: 17924606
    [No Abstract]   [Full Text] [Related]  

  • 17. [Recent advances in gout: pathogenesis, diagnosis, comorbidities, treatment].
    Soós B; Szamosi S; Benkő S; Paragh G; Szekanecz Z
    Orv Hetil; 2018 Oct; 159(40):1625-1636. PubMed ID: 30277413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained Response to Pegloticase Without Infusion Reactions Despite Multiple Lapses in Treatment in Patient With Severe Tophaceous Gout.
    Schmidt JN; Cunningham MA
    J Clin Rheumatol; 2021 Dec; 27(8S):S491-S494. PubMed ID: 31743263
    [No Abstract]   [Full Text] [Related]  

  • 19. Debulking the urate load to feel better.
    Richette P
    J Rheumatol; 2012 Jul; 39(7):1311-3. PubMed ID: 22753797
    [No Abstract]   [Full Text] [Related]  

  • 20. Recapture and improved outcome of pegloticase response with methotrexate-A report of two cases and review of the literature.
    Bessen SY; Bessen MY; Yung CM
    Semin Arthritis Rheum; 2019 Aug; 49(1):56-61. PubMed ID: 30583886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.